Levosimendan Accord

Levosimendan, the active ingredient in Levosimendan Accord, is a calcium sensitizer presented as an intravenous solution for IV use. It enhances cardiac contractility and promotes vasodilation in patients with acute decompensated heart failure.

GNH USA supplies Levosimendan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure syndromes where improved myocardial contractility and vasodilation are required.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Chronic heart failure with reduced ejection fraction (adjunct): provides additional inotropic support when standard therapy is insufficient. Cardiogenic shock (adjunct): offers temporary haemodynamic stabilization in severe low‑output states.

Levosimendan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Dizziness: related to blood pressure changes.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: worsening respiratory status.

Levosimendan requires careful patient assessment and monitoring before and during infusion. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution in patients with liver dysfunction. - Hypotension: observe blood pressure closely, especially when combined with other vasodilators. - History of arrhythmias: continuous ECG monitoring is advised. - Concomitant vasodilators: risk of additive blood pressure reduction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Other calcium sensitizers: risk of excessive inotropy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - Diuretics: potential for volume depletion and hypotension. - ACE inhibitors or ARBs: additive blood pressure lowering. - Nitrates: enhanced vasodilation risk. - Anticoagulants: monitor for bleeding if haemodynamic changes occur.